The Uromigos

Episode 335: Novel immune therapies for renal cancer 19.07.2024 37:31 ↓

David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.

Episode 333: The Uromigos Cup - The Netherlands 05.07.2024 26:20 ↓

Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions

Episode 332: The Uromigos Cup - Germany's Entry 26.06.2024 35:55 ↓

Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football

Episode 331: AUA 2024 NMIBC Highlights 21.06.2024 33:56 ↓

Aditya Bagrodia describes three new drugs/studies in NMIBC.

Episode 330: ASCO 2024 Highlights 10.06.2024 52:47 ↓

Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.

Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies 05.06.2024 26:32 ↓

David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.

Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates 04.06.2024 24:02 ↓

Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.

Episode 326 ASCO24: KIM-1 in Renal Cancer 03.06.2024 18:08 ↓

Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.

Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer 03.06.2024 33:44 ↓

Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.

Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC 02.06.2024 20:43 ↓

Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.

Episode 323 ASCO24: TDXD in Bladder Cancer 02.06.2024 29:47 ↓

Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.

Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC) 02.06.2024 22:16 ↓

Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.

Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original? 01.06.2024 23:25 ↓

Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.

Episode 320: Team Canada's entry for the Uromigos Cup 25.05.2024 23:30 ↓

Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.

Episode 319: ASCO 2024: A Preview of GU Data 19.05.2024 33:49 ↓

What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.

Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases 13.05.2024 31:59 ↓

Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.

Episode 317: AUA 2024 Preview with the AUA Secretary 01.05.2024 22:16 ↓

David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.

Episode 316: APCCC 2024 Summary with Silke Gillessen 28.04.2024 41:11 ↓

Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.

Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer 27.04.2024 18:17 ↓

Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.

Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer 27.04.2024 25:15 ↓

Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.

Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease 26.04.2024 35:40 ↓

Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.

Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer 26.04.2024 23:56 ↓

Jason Efstathiou and Piet Ost discuss the data for and against this approach.

Episode 311: The Uromigos Paper of the Month - The POUT Trial 23.04.2024 36:02 ↓

Alison Birtle describes adjuvant chemotherapy in bladder cancer.

Episode 310: Dosing and duration of drugs from a cost perspective 17.04.2024 28:28 ↓

Daniel Goldstein describes his work on this issue.

Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer 07.04.2024 27:13 ↓

In this second part, Matt Galsky describes the OS signal data. We also look into the future.